Beclometasone controlled-release - Chiesi

Drug Profile

Beclometasone controlled-release - Chiesi

Alternative Names: Beclomethasone controlled-release - Chiesi; Beclomethasone dipropionate controlled-release - Chiesi; CHF-1514; Clipper; EUR-1073

Latest Information Update: 15 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chiesi Farmaceutici
  • Developer Chiesi Farmaceutici; Eurand
  • Class Antiallergics; Antiasthmatics; Chlorinated steroids; Corticosteroids; Pregnadienetriols; Small molecules; Vascular disorder therapies
  • Mechanism of Action Immunosuppressants; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ulcerative colitis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Ulcerative colitis
  • Discontinued Inflammatory bowel diseases

Most Recent Events

  • 16 May 2017 Chiesi initiates enrolment in the BeCalCU phase III trial for Ulcerative colitis in Spain (EudraCT2017-000330-61)
  • 03 Feb 2014 Aptalis has been acquired by Forest Laboratories
  • 11 Feb 2011 Eurand has been acquired and merged into Axcan Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top